Verrica Pharmaceuticals Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Verrica Pharmaceuticals Inc. (VRCA) reported Cash and Cash Equivalents, Period Increase (Decrease) of $9.58 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-07.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-07
- Verrica Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$4.58M, a 106.05% decline year-over-year.
- Verrica Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $14.16M, a 24.79% decline year-over-year.
- Verrica Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$28.04M, a 439.18% decline year-over-year.
- Verrica Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$64.84M.
- Verrica Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $1.61M, a 80.24% decline from fiscal 2017.
- Verrica Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $8.14M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$4.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $9.58M 10-Q · filed 2019-08-07 | -$18.46M derived: sum of 3 quarters · filed 2019-08-07 | -$83.30M derived: sum of 4 quarters · filed 2019-08-07 |
| 2019-03-31 | $14.16M 10-Q · filed 2019-05-07 | -$13.88M derived: sum of 2 quarters · filed 2019-05-07 | -$78.72M derived: sum of 3 quarters · filed 2019-05-07 | -$3.06M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-12-31 | -$28.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$92.88M derived: sum of 2 quarters · filed 2019-03-07 | -$17.21M derived: sum of 3 quarters · filed 2019-08-07 | $1.61M 10-K · filed 2019-03-07 |
| 2018-09-30 | -$64.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $10.83M derived: sum of 2 quarters · filed 2019-08-07 | $29.65M 10-Q · filed 2018-11-07 | $37.91M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-06-30 | $75.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $94.49M 10-Q · filed 2019-08-07 | $102.75M derived: sum of 3 quarters · filed 2019-08-07 | $102.64M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $18.82M 10-Q · filed 2019-05-07 | $27.09M derived: sum of 2 quarters · filed 2019-05-07 | $26.98M derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $8.16M derived: sum of 2 quarters · filed 2019-03-07 | $8.14M 10-K · filed 2019-03-07 | |
| 2017-09-30 | -$110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$131.00K 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$21.00K 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |